Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras
Ioannou G, Berry K, Rajeevan N, Li Y, Yan L, Huang Y, Bui D, Hynes D, Rowneki M, Hickok A, Niederhausen M, Shahoumian T, Bohnert A, Boyko E, Korpak A, Fox A, Baraff A, Iwashyna T, Maciejewski M, Smith V, Berkowitz T, Pura J, Hebert P, Wong E, O’Hare A, Osborne T, Viglianti E, Aslan M, Bajema K. Target Trial Emulation of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus No Infection and Risk of Post–Coronavirus Disease 2019 Conditions in the Omicron Variant Versus Prior Eras. Clinical Infectious Diseases 2025, ciaf087. PMID: 40208261, DOI: 10.1093/cid/ciaf087.Peer-Reviewed Original ResearchPost-COVID-19 conditionCumulative incidence of deathVeterans Health AdministrationMatched index dateCumulative incidence differenceExcess burdenCumulative incidenceBurden of mortalityHypothetical target trialIncidence of deathDeath up to 1 yearTarget trial emulationAll-cause mortalityHealth recordsHealth AdministrationTrial emulationIncidence differencesIndex dateUninfected participantsPost-coronavirus diseaseVeteransUnvaccinated personsTarget trialsOmicron eraVaccination status
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply